​

Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CYTK Stock Forecast

Cytokinetics (CYTK) stock forecast, based on 35 Wall Street analysts, predicts a 12-month average price target of $112.50, with a high of $140.00 and a low of $95.00. This represents a 51.80% increase from the last price of $74.11.

$45 $64 $83 $102 $121 $140 High: $140 Avg: $112.5 Low: $95 Last Closed Price: $74.11

CYTK Stock Rating

Cytokinetics stock's rating consensus is Buy, based on 35 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (97.14%), 1 Hold (2.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 35 1 34 Strong Sell Sell Hold Buy Strong Buy

CYTK Price Target Upside V Benchmarks

TypeNameUpside
StockCytokinetics51.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1831
Avg Price Target$110.00$114.38$99.65
Last Closing Price$74.11$74.11$74.11
Upside/Downside48.43%54.34%34.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 267132--22
Aug, 267132--22
Jul, 267123--22
Jun, 267123--22
May, 267113--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2026Barclays$110.00$75.6445.43%48.43%
Aug 10, 2026Srikripa DevarakondaTruist Financial$112.00$76.4546.50%51.13%
Aug 07, 2026Serge BelangerNeedham$112.00$76.3246.75%51.13%
Aug 07, 2026Leonid TimashevRBC Capital$112.00$77.5944.35%51.13%
Jul 07, 2026Leonid TimashevRBC Capital$117.00$85.5736.73%57.87%
Jun 29, 2026Ashwani VermaUBS$115.00$82.1939.92%55.17%
Jun 24, 2026Mizuho Securities$118.00$80.0147.48%59.22%
Jun 17, 2026Leonid TimashevRBC Capital$119.00$75.2158.22%60.57%
May 11, 2026H.C. Wainwright$140.00$76.9182.03%88.91%
May 06, 2026Morgan Stanley$103.00$73.8239.53%38.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 11, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 01, 2026Morgan StanleyOverweightBuyupgrade
Aug 14, 2026H.C. WainwrightBuyBuyhold
Aug 13, 2026BarclaysOverweightOverweighthold
Aug 07, 2026NeedhamBuyBuyhold
Aug 07, 2026RBC CapitalOutperformOutperformhold
Aug 07, 2026CitigroupOutperformOutperformhold
Aug 07, 2026CitigroupMarket OutperformMarket Outperformhold
Jun 29, 2026UBSNeutralBuyupgrade
Jun 17, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-20 $-13 $-6 $1 $8 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.80$-4.33$-5.45$-5.26$-6.54---
Avg Forecast$-3.26$-4.06$-4.88$-5.24$-5.40$-4.04$-0.26$2.83
High Forecast$0.05$-0.19$-4.35$-4.55$-3.93$-2.50$0.30$11.50
Low Forecast$-14.80$-15.96$-5.34$-5.59$-6.97$-6.50$-1.29$-0.55
Surprise %-14.11%6.65%11.68%0.38%21.11%---

Revenue Forecast

$0 $900M $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$70.43M$94.59M$7.53M$18.47M$88.04M---
Avg Forecast$20.72M$99.32M$21.85M$3.28M$47.78M$292.97M$720.92M$1.24B
High Forecast$77.12M$323.22M$91.92M$14.05M$169.91M$303.62M$757.84M$4.18B
Low Forecast$4.54M$26.48M$9.62M$279.05K$4.13M$282.31M$683.99M$101.57M
Surprise %239.94%-4.76%-65.53%463.28%84.25%---

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-215.31M$-388.95M$-526.24M$-589.53M$-784.96M---
Avg Forecast$-181.31M$-178.74M$-526.24M$-489.37M$-632.39M$-497.99M$-47.73M$272.92M
High Forecast$-145.04M$-142.99M$-421.00M$-439.27M$-379.04M$-240.98M$29.04M$1.11B
Low Forecast$-217.57M$-214.49M$-631.49M$-539.46M$-672.43M$-627.51M$-124.50M$-52.90M
Surprise %18.76%117.61%-20.47%24.13%---

CYTK Forecast FAQ

Is Cytokinetics stock a buy?

Cytokinetics stock has a consensus rating of Buy, based on 35 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cytokinetics is a favorable investment for most analysts.

What is Cytokinetics's price target?

Cytokinetics's price target, set by 35 Wall Street analysts, averages $112.5 over the next 12 months. The price target range spans from $95 at the low end to $140 at the high end, suggesting a potential 51.80% change from the previous closing price of $74.11.

How does Cytokinetics stock forecast compare to its benchmarks?

Cytokinetics's stock forecast shows a 51.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cytokinetics over the past three months?

  • September 2026: 31.82% Strong Buy, 59.09% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 31.82% Strong Buy, 59.09% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 31.82% Strong Buy, 54.55% Buy, 13.64% Hold, 0% Sell, 0% Strong Sell.

What is Cytokinetics’s EPS forecast?

Cytokinetics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.04, marking a -38.23% decrease from the reported $-6.54 in 2025. Estimates for the following years are $-0.26 in 2027, and $2.83 in 2028.

What is Cytokinetics’s revenue forecast?

Cytokinetics's average annual revenue forecast for its fiscal year ending in December 2026 is $292.97M, reflecting a 232.77% increase from the reported $88.04M in 2025. The forecast for 2027 is $720.92M, and $1.24B for 2028.

What is Cytokinetics’s net income forecast?

Cytokinetics's net income forecast for the fiscal year ending in December 2026 stands at $-498M, representing a -36.56% decrease from the reported $-785M in 2025. Projections indicate $-47.73M in 2027, and $272.92M in 2028.